Ultra Long Acting Insulin Degludec Reduces Nocturnal Hypoglycemia, New Studies Show

Two new phase 3 studies published in The Lancet show that ultra long acting insulin, Degludec, an investigational compound from Novo Nordisk, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine.
The two studies included in total 1,635 participants and investigated insulin degludec compared to insulin… Read more

FDA Approves Novo Nordisk’s Levemir Insulin for Pregnant Women with Diabetes

The U.S. FDA has approved Novo Nordisk’s Levemir insulin (insulin detemir [rDNA origin] injection) for use by pregnant women with diabetes, giving it a Category B classification, indicating that it does not increase the risk of harm to the unborn baby.
The label update makes Levemir the first and only basal insulin analog to have this classification… Read more

FDA Approves Novo Nordisk’s Levemir Insulin for Pregnant Women with Diabetes

The U.S. FDA has approved Novo Nordisk’s Levemir insulin (insulin detemir [rDNA origin] injection) for use by pregnant women with diabetes, giving it a Category B classification, indicating that it does not increase the risk of harm to the unborn baby.
The label update makes Levemir the first and only basal insulin analog to have this classification… Read more

Paula Deen’s Diabetes: Are We Getting the Right Message?

The blogosphere was thrumming about whether the Food Network’s down-home Southern queen, Paula Deen, has Type 2 diabetes. Yes, by now you know she does. It doesn’t bother me that she kept it “close to my chest” as she announced … Read more

Subscribe to our Newsletter

Hide me